Bi-aryl 8-Azoniabicyclooctane Antagonists for Long-Acting Inhalation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for airway hyperreactive diseases like asthma and COPD rely on short-acting anti-cholinergic drugs, such as Ipratropium Bromide, which require frequent administration, and there is a need for long-acting, locally active compounds that can effectively block muscarinic acetylcholine receptors in the respiratory tract to reduce side effects.
Innovation Solution
Development of novel bi-aryl 8-azoniabicyclo[3.2.1]octane compounds and their pharmaceutical compositions that can be administered once daily to inhibit acetylcholine binding to muscarinic acetylcholine receptors, providing long-lasting relief with reduced systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If short-acting anti-cholinergic drugs like Ipratropium Bromide are used, then effective blockade of muscarinic acetylcholine receptors is achieved, but frequent administration is required reducing patient compliance and productivity
Solution Approach 1:
The patent modifies the molecular structure of anti-cholinergic drugs by changing chemical parameters (introducing bi-aryl 8-azoniabicyclo[3.2.1]octane compounds with specific substituents) to achieve long-acting pharmacological activity. This structural parameter change enables once-daily administration while maintaining effective receptor blockade, resolving the contradiction between reliability and administration frequency.
Solution Approach 2:
The invention creates a dynamic solution by developing compounds with variable half-lives that extend beyond the traditional short-acting category. The bi-aryl 8-azoniabicyclo[3.2.1]octane compounds provide sustained receptor occupancy over 24 hours, transforming the drug from a short-acting to a long-acting agent, thereby reducing administration frequency while maintaining effectiveness.
2Reliability
If systemic anti-cholinergic therapy is administered, then muscarinic acetylcholine receptor blockade is achieved, but side effects occur
Solution Approach 1:
The patent applies local quality by designing inhaled anti-cholinergic compounds that preferentially target the respiratory tract. The bi-aryl 8-azoniabicyclo[3.2.1]octane compounds are formulated for inhalation delivery, concentrating the drug action in the lungs and airways where muscarinic receptors are located, thereby achieving effective blockade with minimal systemic absorption and reduced side effects.
Solution Approach 2:
The inhaled delivery system acts as an intermediary, allowing the anti-cholinergic compound to reach the respiratory tract receptors directly without extensive systemic circulation. This intermediary delivery mechanism enables selective receptor blockade in the lungs while minimizing exposure to other organ systems, reducing harmful side effects.
3Reliability
If higher doses of anti-cholinergic drugs are used, then better symptom control is achieved, but side effects increase
Solution Approach 1:
The patent changes the pharmacological parameters of the anti-cholinergic agents by using bi-aryl 8-azoniabicyclo[3.2.1]octane compounds with optimized binding affinity and prolonged duration of action. This parameter change allows achievement of effective symptom control at lower doses compared to traditional agents, as the new compounds provide more efficient and sustained receptor blockade, thereby reducing dose-related side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds offer a long-acting solution for treating muscarinic acetylcholine receptor-mediated diseases, providing effective blockade of acetylcholine receptors in the respiratory tract with lower doses and reduced systemic side effects, improving the management of asthma and COPD.
Implementation Method 1
Muscarinic acetylcholine receptor antagonists... provide effective blockade of acetylcholine receptors... inhibit acetylcholine binding to muscarinic acetylcholine receptors
Data Source
AI summary
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.